Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTX401 in Adults With Glycogen Storage Disease Type Ia
NCT03517085Phase 2Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- May 2018
- Primary completion
- Nov 2021
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 4
01
Overview
A Phase 2 trial of pariglasgene brecaparvovec in Glycogen storage disease type Ia (GSDIa), sponsored by Ultragenyx Pharmaceutical Inc.. Started May 2018; status: completed.
02
Drugs
pariglasgene brecaparvovec
03
Conditions
Glycogen storage disease type Ia (GSDIa)
Beyond the preview
Go deeper on NCT03517085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517085.